Back to results
US 10,925,956 B2Granted
Methods and compositions for inducing protective immunity against a marburg virus infection
AssigneesJanssen Vaccines & Prevention B.V., Bavarian Nordic A/S
InventorsBenoit Christophe Stephan Callendret, Ramon Roozendaal, Jutta Sytske Hartkoorn-Pasma, Ariane Volkmann, Robin Steigerwald, Ulrike Dirmeier
Life of this patent
Estimating the term…
Abstract
Compositions, vaccines and methods using a combination of adenovirus vectors and MVA vectors for inducing protective immunity against a Marburg virus infection are described.
Claims18
A combination of an immunogenic composition comprising
- a. a first composition consisting of an immunologically effective amount of an adenovirus vector comprising a nucleic acid encoding a first antigenic protein of a Marburg virus, together with a pharmaceutically acceptable carrier, wherein the first antigenic protein has the amino acid sequence of SEQ ID NO:
- 3, and wherein the first antigenic protein is the only antigen protein encoded by the adenovirus vector;
- and
- b. a second composition comprising an immunologically effective amount of an MVA vector comprising a nucleic acid encoding a second antigenic protein of a Marburg virus, preferably the nucleic acid further encoding one or more antigenic proteins of at least one additional filovirus subtype, together with a pharmaceutically acceptable carrier;
- wherein the first antigenic protein and the second antigenic protein share at least one antigenic determinant, and the first composition is the priming composition and the second composition is the boosting composition.
2 more elements
A method of inducing an immune response against a Marburg virus in a subject, the method comprising:
- a. administering to the subject a first composition consisting of an immunologically effective amount of an adenovirus vector comprising a nucleic acid encoding a first antigenic protein of a Marburg virus, wherein the first antigenic protein has the amino acid sequence of SEQ ID NO:
- 3, and wherein the first antigenic protein is the only antigenic protein encoded by the adenovirus vector;
- and
- b. administering to the subject a second composition comprising an immunologically effective amount of an MVA vector comprising a nucleic acid encoding a second antigenic protein of a Marburg virus, preferably the nucleic acid further encoding one or more antigenic proteins of at least one additional filovirus subtype,
- wherein the first antigenic protein and the second antigenic protein share at least one antigenic determinant, and step (b) is conducted 1-12 weeks, preferably 4 or 8 weeks, after step (a).
2 more elements
A kit comprising:
- a. a first composition consisting of an immunologically effective amount of an adenovirus vector comprising a nucleic acid encoding a first antigenic protein of a Marburg virus, together with a pharmaceutically acceptable carrier, wherein the first antigenic protein has the amino acid sequence of SEQ ID NO:
- 3, and wherein the first antigenic protein is the only antigenic protein encoded by the adenovirus vector;
- and
- b. a second composition comprising an immunologically effective amount of an MVA vector comprising a nucleic acid encoding a second antigenic protein of a Marburg virus, preferably the nucleic acid further encoding one or more antigenic proteins of at least one additional filovirus subtype, together with a pharmaceutically acceptable carrier;
- wherein the first antigenic protein and the second antigenic protein share at least one antigenic determinant, and the first composition is the priming composition and the second composition is the boosting composition.
2 more elements
Dependencies are inferred from the claim text.